Prevention of Chronic Renal Diseases in the Elderly

  • Sanjib Kumar Sharma
  • Norberto Perico
  • Piero Ruggenenti
  • Giuseppe Remuzzi


Chronic Kidney Disease Diabetic Nephropathy Renal Replacement Therapy Autosomal Dominant Polycystic Kidney Disease Chronic Renal Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Incidence and prevalence of ESRD. USRDS. United States Renal Data System. Am. J. Kidney Dis. 1997; 30:S40–53.Google Scholar
  2. Usami, T., Koyama, K., Takeuchi, O., Morozumi, K., Kimura, G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA 2000; 284:2622–2624.PubMedCrossRefGoogle Scholar
  3. Disney, A.P. Some trends in chronic renal replacement therapy in Australia and New Zealand. Nephrol. Dial. Transplant. 1998; 13:854–859.PubMedCrossRefGoogle Scholar
  4. Report. Dialysis and Renal Transplantation, Canadian Organ Replacement Register. Ottawa, Ontario: Canadian Institute for Health Information. 2001.Google Scholar
  5. Frei, U., Schober-Halstenberg, H.J. Annual Report of the German Renal Registry 1998. QuaSi-Niere Task Group for Quality Assurance in Renal Replacement Therapy. Nephrol. Dial. Transplant 1999; 14:1085–1090.PubMedCrossRefGoogle Scholar
  6. Garcia Lopez, F.J., Robles, R., Gentil, M.A. En presentacion del Grupo de Registros de Enfermos Renales de Espana. Comparacion de la incidencia, prevalencia, modalidades de tratamiento y mortalidad en pacientes con tratamiento renal sustitutivo en cinco communidades autonomas espagnolas en el periodo 1991–1996. Nefrologia 1999; 19:443–459.Google Scholar
  7. U.R.R.R. 2000. UK Renal Registry. Bristol, UK.Google Scholar
  8. Jungers, P., Choukroun, G., Robino, C., Massy, Z.A., Taupin, P., Labrunie, M., Man, N.K., Landais, P. Epidemiology of end-stage renal disease in the Ile-de-France area: A prospective study in 1998. Nephrol. Dial. Transplant 2000; 15:2000–2006.PubMedCrossRefGoogle Scholar
  9. Stengel, B., Billon, S., Van Dijk, P.C., Jager, K.J., Dekker, F.W., Simpson, K., Briggs, J.D. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990–1999. Nephrol. Dial. Transplant 2003; 18:1824–1833.PubMedCrossRefGoogle Scholar
  10. McCredie, M. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998–2002. Nephrol. Dial. Transplant 2006; 21:2178–2183.PubMedCrossRefGoogle Scholar
  11. Coresh, J., Astor, B.C., Greene, T., Eknoyan, G., Levey, A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003; 41:1–12.PubMedCrossRefGoogle Scholar
  12. Hannedouche, T., Landais, P., Goldfarb, B., el Esper, N., Fournier, A., Godin, M., Durand, D., Chanard, J., Mignon, F., Suo, J.M., et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309:833–837.PubMedGoogle Scholar
  13. Bigazzi, R., Bianchi, S., Baldari, D., Campese, V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J. Hypertens. 1998; 16:1325–1333.PubMedCrossRefGoogle Scholar
  14. Magnason, R.L., Indridason, O.S., Sigvaldason, H., Sigfusson, N., Palsson, R. Prevalence and progression of CRF in Iceland: a population-based study. Am. J. Kidney Dis. 2002; 40:955–963.PubMedCrossRefGoogle Scholar
  15. Jungers, P., Chauveau, P., Descamps-Latscha, B., Labrunie, M., Giraud, E., Man, N.K., Grunfeld, J.P., Jacobs, C. Age- and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrol. Dial. Transplant 1996; 11:1542–1546.PubMedGoogle Scholar
  16. John, R., Webb, M., Young, A., Stevens, P.E. Unreferred chronic kidney disease: A longitudinal study. Am. J. Kidney Dis. 2004; 43:825–835.PubMedCrossRefGoogle Scholar
  17. Simal, F., Martin Escudero, J.C., Bellido, J., Arzua, D., Mena, F.J., Gonzalez Melgosa, I., Alvarez Hurtado, A.A., Tabuyo, M.B., Molina, A. [Prevalence of mild to moderate chronic kidney disease in the general population of Spain. Hortega study.] [in Spanish] Nefrologia 2004; 24:329–332, 334, 336–327.Google Scholar
  18. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39(Suppl 1):S1–S266.Google Scholar
  19. Glynn, R.J., Chae, C.U., Guralnik, J.M., Taylor, J.O., Hennekens, C.H. Pulse pressure and mortality in older people. Arch. Intern. Med. 2000; 160:2765–2772.PubMedCrossRefGoogle Scholar
  20. Caskey, F.J., Schober-Halstenberg, H.J., Roderick, P.J., Edenharter, G., Ansell, D., Frei, U., Feest, T.G. Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am. J. Kidney Dis. 2006; 47:445–454.PubMedCrossRefGoogle Scholar
  21. Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag, M.J., et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154–2169.PubMedCrossRefGoogle Scholar
  22. Hansberry, M.R., Whittier, W.L., Krause, M.W. The elderly patient with chronic kidney disease. Adv. Chronic Kidney Dis. 2005; 12:71–77.PubMedCrossRefGoogle Scholar
  23. Harris, M.I., Flegal, K.M., Cowie, C.C., Eberhardt, M.S., Goldstein, D.E., Little, R.R., Wiedmeyer, H.M., Byrd-Holt, D.D. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998; 21:518–524.PubMedCrossRefGoogle Scholar
  24. Kamper, A.L., Strandgaard, S., Leyssac, P.P. Late outcome of a controlled trial of enalapril treatment in progressive chronic renal failure. Hard end-points and influence of proteinuria. Nephrol. Dial. Transplant 1995; 10:1182–1188.PubMedGoogle Scholar
  25. Buemi, M., Nostro, L., Aloisi, C., Cosentini, V., Criseo, M., Frisina, N. Kidney aging: From phenotype to genetics. Rejuvenation Res. 2005; 8:101–109.PubMedCrossRefGoogle Scholar
  26. Burstein, D.M., Korbet, S.M., Schwartz, M.M. Membranous glomerulonephritis and malignancy. Am. J. Kidney Dis. 1993; 22:5–10.PubMedGoogle Scholar
  27. Haas, M., Spargo, B.H., Wit, E.J., Meehan, S.M. Etiologies and outcome of acute renal insufficiency in older adults: A renal biopsy study of 259 cases. Am. J. Kidney Dis. 2000; 35:433–447.PubMedGoogle Scholar
  28. Modesto-Segonds, A., Ah-Soune, M.F., Durand, D., Suc, J.M. Renal biopsy in the elderly. Am. J. Nephrol. 1993; 13:27–34.PubMedCrossRefGoogle Scholar
  29. Preston, R.A., Stemmer, C.L., Materson, B.J., Perez-Stable, E., Pardo, V. Renal biopsy in patients 65 years of age or older. An analysis of the results of 334 biopsies. J. Am. Geriatr. Soc. 1990; 38:669–674.PubMedGoogle Scholar
  30. Davison, A.M. Renal disease in the elderly. Nephron 1998; 80:6–16.PubMedCrossRefGoogle Scholar
  31. Ruggenenti, P., Remuzzi, A., Ondei, P., Fasolini, G., Antiga, L., Ene-Iordache, B., Remuzzi, G., Epstein, F.H. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005; 68:206–216.PubMedCrossRefGoogle Scholar
  32. Johnson, A.M., Gabow, P.A. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J. Am. Soc. Nephrol. 1997; 8:1560–1567.PubMedGoogle Scholar
  33. King, B.F., Reed, J.E., Bergstralh, E.J., Sheedy, P.F., II, Torres, V.E. Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2000; 11:1505–1511.PubMedGoogle Scholar
  34. Klag, M.J., Whelton, P.K., Randall, B.L., Neaton, J.D., Brancati, F.L., Ford, C.E., Shulman, N.B., Stamler, J. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996; 334:13–18.PubMedCrossRefGoogle Scholar
  35. Perneger, T.V., Whelton, P.K., Klag, M.J. History of hypertension in patients treated for end-stage renal disease. J. Hypertens. 1997; 15:451–456.PubMedCrossRefGoogle Scholar
  36. Psaty, B.M., Furberg, C.D., Kuller, L.H., Cushman, M., Savage, P.J., Levine, D., O’Leary, D.H., Bryan, R.N., Anderson, M., Lumley, T. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: The cardiovascular health study. Arch. Intern. Med. 2001; 161:1183–1192.PubMedCrossRefGoogle Scholar
  37. Benetos, A., Safar, M., Rudnichi, A., Smulyan, H., Richard, J.L., Ducimetieere, P., Guize, L. Pulse pressure: A predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410–1415.PubMedGoogle Scholar
  38. Franklin, S.S., Khan, S.A., Wong, N.D., Larson, M.G., Levy, D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999; 100:354–360.PubMedGoogle Scholar
  39. Chae, C.U., Pfeffer, M.A., Glynn, R.J., Mitchell, G.F., Taylor, J.O., Hennekens, C.H. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999; 281:634–639.PubMedCrossRefGoogle Scholar
  40. Sesso, H.D., Stampfer, M.J., Rosner, B., Hennekens, C.H., Gaziano, J.M., Manson, J.E., Glynn, R.J. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension 2000; 36:801–807.PubMedGoogle Scholar
  41. Blacher, J., Staessen, J.A., Girerd, X., Gasowski, J., Thijs, L., Liu, L., Wang, J.G., Fagard, R.H., Safar, M.E. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch. Intern. Med. 2000; 160:1085–1089.PubMedCrossRefGoogle Scholar
  42. Vaccarino, V., Holford, T.R., Krumholz, H.M. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J. Am. Coll. Cardiol. 2000; 36:130–138.PubMedCrossRefGoogle Scholar
  43. Rosen, A.B., Karter, A.J., Liu, J.Y., Selby, J.V., Schneider, E.C. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J. Gen. Intern. Med. 2004; 19:669–675.PubMedCrossRefGoogle Scholar
  44. Young, J.H., Klag, M.J., Muntner, P., Whyte, J.L., Pahor, M., Coresh, J. Blood pressure and decline in kidney function: Findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 2002; 13:2776–2782.PubMedCrossRefGoogle Scholar
  45. Hyman, D.J., Pavlik, V.N. Characteristics of patients with uncontrolled hypertension in the United States. N. Engl. J. Med. 2001; 345:479–486.PubMedCrossRefGoogle Scholar
  46. Hansen, K.J., Edwards, M.S., Craven, T.E., Cherr, G.S., Jackson, S.A., Appel, R.G., Burke, G.L., Dean, R.H. Prevalence of renovascular disease in the elderly: A population-based study. J. Vasc. Surg. 2002; 36:443–451.PubMedCrossRefGoogle Scholar
  47. Wild, S., Roglic, G., Green, A., Sicree, R., King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047–1053.PubMedCrossRefGoogle Scholar
  48. U.S.R.D. System USRDS 2003 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2003.Google Scholar
  49. Mokdad, A.H., Ford, E.S., Bowman, B.A., Nelson, D.E., Engelgau, M.M., Vinicor, F., Marks, J.S. Diabetes trends in the U.S.: 1990–1998. Diabetes Care 2000; 23:1278–1283.PubMedCrossRefGoogle Scholar
  50. Lee, G. End-stage renal disease in the Asian-Pacific region. Semin. Nephrol. 2003; 23:107–114.PubMedCrossRefGoogle Scholar
  51. Van Dijk, P.C., Jager, K.J., Stengel, B., Gronhagen-Riska, C., Feest, T.G., Briggs, J.D. Renal replacement therapy for diabetic end-stage renal disease: Data from 10 registries in Europe (1991–2000). Kidney Int. 2005; 67:1489–1499.PubMedCrossRefGoogle Scholar
  52. Anderson, S., Rennke, H.G., Brenner, B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77:1993–2000.PubMedGoogle Scholar
  53. Aros, C., Remuzzi, G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J. Hypertens. Suppl. 2002; 20:S45–53.PubMedCrossRefGoogle Scholar
  54. Shake, J.G., Brandt, R.C., Daniels, B.S. Angiotensin II induces actine in the polymerization within the glomerular filtration barrier: Possible role in the local regulation of ultrafiltration. J. Am. Soc. Nephrol. 1992; 3:568A.Google Scholar
  55. Wolf, G., Kalluri, R., Ziyadeh, F.N., Neilson, E.G., Stahl, R.A. Angiotensin II induces alpha3(IV) collagen expression in cultured murine proximal tubular cells. Proc. Assoc. Am. Physicians 1999; 111:357–364.PubMedCrossRefGoogle Scholar
  56. Zoja, C., Benigni, A., Remuzzi, G. Cellular responses to protein overload: Key event in renal disease progression. Curr. Opin. Nephrol. Hypertens. 2004; 13:31–37.PubMedCrossRefGoogle Scholar
  57. Eddy, A. Role of cellular infiltrates in response to proteinuria. Am. J. Kidney Dis. 2001; 37:S25–29.PubMedGoogle Scholar
  58. Agapitov, A.V., Haynes, W.G. Role of endothelin in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2002; 3:1–15.PubMedCrossRefGoogle Scholar
  59. Komatsu, K., Frohlich, E.D., Ono, H., Ono, Y., Numabe, A., Willis, G.W. Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension 2005; 25:207–213.Google Scholar
  60. Frohlich, E.D. Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 1997; 29:188–193.Google Scholar
  61. Harris, P.C., Torres, V.E. Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy. Curr. Opin. Nephrol. Hypertens. 2006; 15:456–463.PubMedCrossRefGoogle Scholar
  62. Peterson, J.C., Adler, S., Burkart, J.M., Greene, T., Hebert, L.A., Hunsicker, L.G., King, A.J., Klahr, S., Massry, S.G., Seifter, J.L. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 1995; 123:754–762.PubMedGoogle Scholar
  63. Wapstra, F.H., Navis, G., de Jong, P.E., de Zeeuw, D. Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease. Exp. Nephrol. 1996; 4 (Suppl 1):47–52.PubMedGoogle Scholar
  64. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345:851–860.PubMedCrossRefGoogle Scholar
  65. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349:1857–1863.Google Scholar
  66. Ruggenenti, P., Perna, A., Mosconi, L., Pisoni, R., Remuzzi, G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int. 1998; 53:1209–1216.PubMedCrossRefGoogle Scholar
  67. Jafar, T.H., Schmidt, C.H., Stark, P.C., Landa, M., Maschio, G., Marcantoni, C., De Jong, P.E., De Zeeuw, D., Shahinfar, S., Levey, A.S. The influence of urine protein excretion on benefit of angiotensin-converting enzyme inhibitors in patients with non-diabetic renal disease. J. Am. Soc. Nephrol. 2000; 11:63A.Google Scholar
  68. Bakris, G.L., Weir, M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch. Intern. Med. 2000; 160:685–693.PubMedCrossRefGoogle Scholar
  69. Ruggenenti, P., Perna, A., Remuzzi, G. ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop: A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J. Am. Soc. Nephrol. 2001; 12:2832–2837.PubMedGoogle Scholar
  70. Acone, D., Cante, D., Cillo, F., Giordano, G., Giordano, C. Blood pressure and progression of renal failure in the elderly. Kidney Int. Suppl. 1996; 55:S75–77.PubMedGoogle Scholar
  71. Pitt, B., Segal, R., Martinez, F.A., Meurers, G., Cowley, A.J., Thomas, I., Deedwania, P.C., Ney, D.E., Snavely, D.B., Chang, P.I. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747–752.PubMedCrossRefGoogle Scholar
  72. Ruggenenti, P., Perna, A., Gherardi, G., Gaspari, F., Benini, R., Remuzzi, G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352:1252–1256.PubMedCrossRefGoogle Scholar
  73. Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J.F., Motolese, M., Ponticelli, C., Ritz, E., Zucchelli, P. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334:939–945.PubMedCrossRefGoogle Scholar
  74. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 2004; 43:S1–290.Google Scholar
  75. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345:861–869.PubMedCrossRefGoogle Scholar
  76. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345:870–878.PubMedCrossRefGoogle Scholar
  77. Remuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B.D., de Zeeuw, D., Hille, D.A., Shahinfar, S., Carides, G.W., Brenner, B.M. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. 2004; 15:3117–3125.PubMedCrossRefGoogle Scholar
  78. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Grunfeld, J.P., Keane, W.F., Kurokawa, K., McGill, J.B., Mitch, W.E., Parving, H.H., Remuzzi, G., et al. The losartan renal protection study—rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J. Renin Angiotensin Aldosterone Syst. 2000; 1:328–335.PubMedCrossRefGoogle Scholar
  79. Winkelmayer, W.C., Zhang, Z., Shahinfar, S., Cooper, M.E., Avorn, J., Brenner, B.M. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006; 29:2210–2217.PubMedCrossRefGoogle Scholar
  80. Winkelmayer, W.C., Fischer, M.A., Schneeweiss, S., Wang, P.S., Levin, R., Avorn, J. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am. J. Kidney Dis. 2005; 46:1080–1087.PubMedCrossRefGoogle Scholar
  81. Rosen, A.B., Hamel, M.B., Weinstein, M.C., Cutler, D.M., Fendrick, A.M., Vijan, S. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann. Intern. Med. 2005; 143:89–99.PubMedGoogle Scholar
  82. Ahuja, T.S., Freeman, D., Jr., Mahnken, J.D., Agraharkar, M., Siddiqui, M., Memon, A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am. J. Nephrol. 2000; 20:268–272.PubMedCrossRefGoogle Scholar
  83. Ruggenenti, P., Schieppati, A., Remuzzi, G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357:1601–1608.PubMedCrossRefGoogle Scholar
  84. Parving, H.H. Diabetic nephropathy: Prevention and treatment. Kidney Int. 2001; 60:2041–2055.PubMedCrossRefGoogle Scholar
  85. Fried, L.F., Orchard, T.J., Kasiske, B.L. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int. 2001; 59:260–269.PubMedCrossRefGoogle Scholar
  86. Lewis, S.J., Moye, L.A., Sacks, F.M., Johnstone, D.E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S.P., Grant, J., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann. Intern. Med. 1998; 129:681–689.PubMedGoogle Scholar
  87. Sacks, F.M., Tonkin, A.M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C.M., Keech, A., Packard, C., Simes, J., Byington, R., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893–1900.PubMedGoogle Scholar
  88. The Merck Manual of Geriatrics. New York, Wiley: Beer MH. 2006.Google Scholar
  89. Hostetter, T.H. The next treatments of chronic kidney disease: If we find them, can we test them? J. Am. Soc. Nephrol. 2002; 13:3024–3026.PubMedCrossRefGoogle Scholar
  90. Orth, S.R., Stockmann, A., Conradt, C., Ritz, E., Ferro, M., Kreusser, W., Piccoli, G., Rambausek, M., Roccatello, D., Schafer, K., et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int. 1998; 54:926–931.PubMedCrossRefGoogle Scholar
  91. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348:383–393.PubMedCrossRefGoogle Scholar
  92. Wolf, G., Ziyadeh, F.N. Renal tubular hypertrophy induced by angiotensin II. Semin. Nephrol. 1997; 17:448–454.PubMedGoogle Scholar
  93. Ritz, E., Orth, S.R. Nephropathy in patients with type 2 diabetes mellitus. N. Engl. J. Med. 1999; 341:1127–1133.PubMedCrossRefGoogle Scholar
  94. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., Menard, J., Rahn, K.H., Wedel, H., Westerling, S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755–1762.PubMedCrossRefGoogle Scholar
  95. Klijn, C.J., Kappelle, L.J., Tulleken, C.A., van Gijn, J. Symptomatic carotid artery occlusion. A reappraisal of hemodynamic factors. Stroke 1997; 28:2084–2093.PubMedGoogle Scholar
  96. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033–1041.Google Scholar
  97. Matsumura, M., Nomura, H., Koni, I., Mabuchi, H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. Nephron 1997; 77:164–168.PubMedGoogle Scholar
  98. Schmidt, A., Gruber, U., Bohmig, G., Koller, E., Mayer, G. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol. Dial. Transplant 2001; 16:1034–1037.PubMedCrossRefGoogle Scholar
  99. Ruilope, L.M., Aldigier, J.C., Ponticelli, C., Oddou-Stock, P., Botteri, F., Mann, J.F. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J. Hypertens. 2000; 18:89–95.PubMedGoogle Scholar
  100. Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., Ideura, T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 2003; 361:117–124.PubMedCrossRefGoogle Scholar
  101. Jamerson, K.A. Preventing chronic kidney disease in special populations. Am. J. Hypertens. 2005; 18:106S–111S.PubMedCrossRefGoogle Scholar
  102. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265:3255–3264.Google Scholar
  103. Staessen, J.A., Fagard, R., Thijs, L., Celis, H., Arabidze, G.G., Birkenhager, W.H., Bulpitt, C.J., de Leeuw, P.W., Dollery, C.T., Fletcher, A.E., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757–764.PubMedCrossRefGoogle Scholar
  104. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., Jr., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T., Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289:2560–2572.PubMedCrossRefGoogle Scholar
  105. Marin, R., Gorostidi, M., Fernandez-Vega, F., Alvarez-Navascues, R. Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis. Kidney Int Suppl. 2005; pp. S52–56.Google Scholar
  106. Wright, J.T., Jr., Bakris, G., Greene, T., Agodoa, L.Y., Appel, L.J., Charleston, J., Cheek, D., Douglas-Baltimore, J.G., Gassman, J., Glassock, R., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 2002; 288:2421–2431.PubMedCrossRefGoogle Scholar
  107. Segura, J., Campo, C., Rodicio, J.L., Ruilope, L.M. ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. Hypertension 2001; 38:645–649.PubMedCrossRefGoogle Scholar
  108. Ritz, E. Albuminuria and vascular damage—The vicious twins. N. Engl. J. Med. 2001; 348:2349–2352.CrossRefGoogle Scholar
  109. Gall, M.A., Hougaard, P., Borch-Johnsen, K., Parving, H.H. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ 1997; 314:783–788.PubMedGoogle Scholar
  110. Adler, A.I., Stevens, R.J., Manley, S.E., Bilous, R.W., Cull, C.A., Holman, R.R. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63:225–232.PubMedCrossRefGoogle Scholar
  111. Perkins, B.A., Ficociello, L.H., Silva, K.H., Finkelstein, D.M., Warram, J.H., Krolewski, A.S. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2003; 348:2285–2293.PubMedCrossRefGoogle Scholar
  112. Mogensen, C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med. 1984; 310:356–360.PubMedCrossRefGoogle Scholar
  113. Nelson, R.G., Knowler, W.C., Pettitt, D.J., Saad, M.F., Charles, M.A., Bennett, P.H. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch. Intern. Med. 1991; 151:1761–1765.PubMedCrossRefGoogle Scholar
  114. Eurich, D.T., Majumdar, S.R., Tsuyuki, R.T., Johnson, J.A. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004; 27:1330–1334.PubMedCrossRefGoogle Scholar
  115. Parving, H.H., Mauer, M., Ritz, E. Diabetic Nephropaty. Philadelphia: Saunders. 2004; pp. 1777–1818.Google Scholar
  116. Ravid, M., Brosh, D., Levi, Z., Bar-Dayan, Y., Ravid, D., Rachmani, R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1998; 128:982–988.PubMedGoogle Scholar
  117. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics. Cont. Clin. Trials 2003; 24:442–461.CrossRefGoogle Scholar
  118. Ruggenenti, P., Fassi, A., Ilieva, A.P., Bruno, S., Iliev, I.P., Brusegan, V., Rubis, N., Gherardi, G., Arnoldi, F., Ganeva, M., et al. Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351:1941–1951.PubMedCrossRefGoogle Scholar
  119. Ruggenenti, P., Perna, A., Ganeva, M., Ene-Iordache, B., Remuzzi, G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: A post hoc analysis of the BENEDICT trial. J. Am. Soc. Nephrol. 2006; 17:3472–3481.PubMedCrossRefGoogle Scholar
  120. Bakris, G.L., Weir, M.R., Shanifar, S., Zhang, Z., Douglas, J., van Dijk, D.J., Brenner, B.M. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch. Intern. Med. 2003; 163:1555–1565.PubMedCrossRefGoogle Scholar
  121. Pohl, M.A., Blumenthal, S., Cordonnier, D.J., De Alvaro, F., Deferrari, G., Eisner, G., Esmatjes, E., Gilbert, R.E., Hunsicker, L.G., de Faria, J.B., et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J. Am. Soc. Nephrol. 2005; 16:3027–3037.PubMedCrossRefGoogle Scholar
  122. Remuzzi, G., Macia, M., Ruggenenti, P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J. Am. Soc. Nephrol. 2006; 17:S90–97.PubMedCrossRefGoogle Scholar
  123. Mogensen, C.E. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand. J. Clin. Lab. Invest. 1976; 36:383–388.PubMedCrossRefGoogle Scholar
  124. Dillon, J.J. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am. J. Kidney Dis. 1993; 22:798–802.PubMedGoogle Scholar
  125. Strippoli, G.F., Craig, M., Schena, F.P., Craig, J.C. Antihypertensive agents for primary prevention of diabetic nephropathy. J. Am. Soc. Nephrol. 2005; 16:3081–3091.PubMedCrossRefGoogle Scholar
  126. Arauz-Pacheco, C., Parrott, M.A., Raskin, P. Hypertension management in adults with diabetes. Diabetes Care 2005; 27 (Suppl 1):S65–67.Google Scholar
  127. Ruggenenti, P., Remuzzi, G. Time to abandon microalbuminuria? Kidney Int. 2006; 70:1214–1222.PubMedCrossRefGoogle Scholar
  128. Collins, A.J. The hemoglobin link to adverse outcomes. Adv. Stud. Med. 2003; 3:S14–S17.Google Scholar
  129. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., Nathan, D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346:393–403.PubMedCrossRefGoogle Scholar
  130. Tuomilehto, J., Lindstrom, J., Eriksson, J.G., Valle, T.T., Hamalainen, H., Ilanne-Parikka, P., Keinanen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344:1343–1350.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sanjib Kumar Sharma
  • Norberto Perico
  • Piero Ruggenenti
  • Giuseppe Remuzzi

There are no affiliations available

Personalised recommendations